By a News Reporter-Staff News Editor at VerticalNews Health WASHINGTON, D.C., A good drug is hard to design: to garner FDA approval and reach consumers, it must not only effectively treat a medical condition, but it must also do so without having side effects that outweigh its benefits. Now, a group of researchers from Weill Cornell Medical Colle
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA New research indicates that hormonal intrauterine devices and contraceptive implants remain highly effective one year beyond their approved duration of use, according to a study at Washington University School of Medicine in St. Louis. The researchers are evaluating whether su
By a News Reporter-Staff News Editor at Heart Disease Weekly Betta Pharmaceuticals Co., Ltd. has been issued patent number 8951959, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. The patent's inventors are Wang, Yinxiang; Tan, Fenlai; Hu, Shaojing; Zhao, Xiangdong; Ma, Cunbo; Wang, Yanping; Shen, Xiaoyan;
By a News Reporter-Staff News Editor at Heart Disease Weekly INO Therapeutics LLC has been issued patent number 8951579, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. The patent's inventor is Baldassarre, James S.. This patent was filed on August 4, 2014 and was published online on February 10, 2015.
By a News Reporter-Staff News Editor at Heart Disease Weekly A patent by the inventor Baldassarre, James S., filed on August 7, 2014, was published online on February 10, 2015, according to news reporting originating from Alexandria, Virginia, by NewsRx correspondents. Patent number 8951580 is assigned to INO Therapeutics LLC. The following quote
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA Investigators publish new report on Halogens. According to news reporting from Tucson, Arizona, by NewsRx journalists, research stated, "The diversity of elements among U.S. Food and Drug Administration approved pharmaceuticals is analyzed and reported, with a focus on atoms o
Baltimore s Asklepion Pharmaceuticals which counts the New Zealand breakfast cereal maker as an investor secured an acquisition agreement with New York- based Retrophin in January. Retrophin has acquired the worldwide rights to Asklepion s colic acid treatment for a deadly genetic liver defect, provided the drug receives US Food and Dru
By a News Reporter-Staff News Editor at VerticalNews Science DALLAS- The common practice of excluding patients with a prior cancer diagnosis from lung cancer clinical trials may not be justified, according to a study by researchers from UT Southwestern Medical Center. Having previously had cancer did not impact clinical outcomes in advanced lung
By a News Reporter-Staff News Editor at VerticalNews Health& Science- An RTP-based pharmaceutical company with roots at the University of North Carolina at Chapel Hill has received $33 million in Series B venture capital funding to develop more effective and less toxic methods to treat patients with cancer. The Series B syndicate is led by Eshelm
Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today reported new preliminary data from the DART study, an ongoing phase 2 clinical trial of dalantercept in patients with advanced renal cell...
Aegerion Pharmaceuticals, Inc., an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating rare diseases, announced today its alliance with the National Organization for Rare Disorders, Rare Diseases Europe and Canadian Organization of Rare Disorders, and The Global Genes...
Speaking before the House Labor, Health and Social Services Committee, he said it takes tens of million dollars and an average of eight to 10 years for a drug to work its way through the FDA approval process. Since people with terminal illnesses don't have the luxury of waiting for those drugs to be approved, Burns said SF 3 would instead make it l
Endocyte, Inc., a biopharmaceutical company and leader in developing targeted small molecule drug conjugates and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that data from ongoing phase 1 trials of Endocyte's SMDCs EC1456 and EC1169 will be presented at the 13 th International Congress o
TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases, today reported positive results from a Phase 1 b clinical trial combining TRC105 with Inlyta in patients with advanced or...
By a News Reporter-Staff News Editor at Investment Weekly News- An RTP-based pharmaceutical company with roots at the University of North Carolina at Chapel Hill has received $33 million in Series B venture capital funding to develop more effective and less toxic methods to treat patients with cancer. The Series B syndicate is led by Eshelman Ven
Amgen and its subsidiary Onyx Pharmaceuticals, Inc., today announced that the European Medicines Agency has accepted the Marketing Authorization Application of Kyprolis for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. Achieving deep and durable responses for patients with...
"Automated Test Apparatus for Testing Risk and Integrity of Pharmaceutical Filtration Membranes and Method Thereof" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Health& Medicine Week A patent application by the inventors Li, Ming-Hsin; Chiu, Shu-Pei; Chang, Chih-Hsien; Lee, Te-Wei, filed on August 1, 2013, was m
In July 2014, Abbott announced that it will sell its developed markets branded generics pharmaceuticals business to Mylan Inc. for 110 million shares of a newly formed publically traded entity that will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business. On January 1, 2013, Abbott completed the separation of..
The product is the company's only drug candidate and Acasti hopes to market it for treatment of hypertriglyceridemia, a condition which can lead to cardiovascular disease. Acasti received notice November 11 that failed to meet the Nasdaq minimum $1 bid listing requirement and that it had 180 days to comply.=========================================
We market three FDA- approved therapies, including Ampyra Extended Release Tablets, 10 mg, a treatment to improve walking in patients with multiple sclerosis, or MS, as demonstrated by an increase in walking speed. In October 2014, we acquired Civitas Therapeutics, Inc., a biopharmaceutical company which is developing CVT-301, a Phase 3 treatment c
DUBLIN and SAN FRANCISCO, Feb. 27, 2015/ PRNewswire/ Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA? by the U.S. Food and Drug Administration for use by women to prevent pregnancy for up to three years. Actavis and Medic
By a News Reporter-Staff News Editor at Health& Medicine Week Actavis plc, a leading global specialty pharmaceutical company, announced the launch of the "Unconditional Love" campaign, which recognizes the "unconditional love" shared by patients with Alzheimer's disease and their caregivers. In partnership with caregiver Betsy Broyles and the "Th
Our lead product candidate, once-daily, triple-action RhopressaTM, successfully completed a Phase 2 b clinical trial in patients with open-angle glaucoma and ocular hypertension in May 2013. Phase 3 registration trials commenced in July 2014. In addition, we are conducting a one year, safety-only study in Canada, named "Rocket 3." Pending successfu
Akorn, Inc., a specialty generic pharmaceutical company, announced today that Tim Dick, Chief Financial Officer, will provide an overview and update of the Company's business at the Barclays Global Healthcare Conference on Thursday, March 12, 2015 at 10:15 a.m. EDT at the Loews Miami Beach Hotel in Miami Beach, Florida. Akorn, Inc. is a specialty
AMAG Pharmaceuticals, Inc. today announced that William Heiden, AMAG's president and chief executive officer, will present at the Cowen and Company 35 th Annual Healthcare Conference on Monday, March 2, 2015 at 2:10 p.m. ET in Boston. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website for 30 days.